Abstract:Background. Lung adenocarcinoma (LUAD) has been recognized as one of the commonest aggressive malignant tumors occurring in humans. The transforming acidic coiled-coil-containing protein 3 (TACC3) seems to be a probable prognostic marker and treatment target for non-small-cell lung cancer (NSCLC). Nevertheless, there exist no reports on the association between TACC3 and immunotherapy or other therapeutic interventions in LUAD. Methods. Premised on the data accessed from The Cancer Genome Atlas- (TCGA-) LUAD, we carried out bioinformatics analysis. The TACC3 expression in LUAD was analyzed utilizing the GEPIA. A survival module was constructed to evaluate the effect of TACC3 on the survival of patients with LUAD. Logistic regression was undertaken to examine the relationship between TACC3 expression and clinical factors. Protein-protein interaction analysis was performed in the GeneMANIA database, and enrichment analysis and identification of predicted signaling pathways were performed using Gene Ontology and Kyoto Encyclopedia of Genes. Additionally, the Cox regression was used to assess the clinicopathologic features linked to the overall survival in TCGA patients. Lastly, we investigated the link between TACC3 and tumor-infiltrating immune cells (TIICs) through CIBERSORT and the "Correlation " module of GEPIA. The association between TACC3 gene expression and drug response was analyzed using the CellMiner database to predict drug sensitivity. Results. The outcomes illustrated that TACC3 was upregulated and considerably correlated with dismal prognosis in LUAD patients. Moreover, the multivariate Cox regression analysis depicted TACC3 as an independent prognostic marker in LUAD patients. It was also revealed that the expression of TACC3 was related to clinical stage (P=0.014), age (P=0.002), and T classification (P <= 0.018). Moreover, we discovered that the expression of TACC3 was considerably linked to a wide range of TIICs, especially the T cells and NK cells. Single-cell results found that TACC3 was mainly expressed in the immune cells (especially tprolif cells) and malignant cells. TACC3 gene expression was positively correlated with TMB and MSI, and TACC3 may provide a prediction of the efficacy of immunotherapy. Moreover, the correlation analysis between TACC3 gene expression and immune checkpoint gene expression revealed that TACC3 may coordinate the activities of these ICP genes in different signal transduction pathways. TACC3 is related to biological progress (BP), cellular component (CC), and molecular function (MF). The pathways involved in the interaction network involving TACC3 include nonhomologous end-joining, RNA transport, pantothenate and CoA biosynthesis, homologous recombination, and nucleotide excision repair. Furthermore, we investigated the association between the expression of TACC3 and the use of antitumor drugs, and TACC3 was positively correlated with response to most drugs. Conclusion. The findings from this research offer robust proof that the expression of TACC3 could be a prognostic marker correlated with TIICs in LUAD. TACC3 can also provide new ideas for immunotherapy as a potential therapeutic target.

Activating transcription factor 3 is a new biomarker correlation with renal clear cell carcinoma progression

ATF4/NUPR1 Axis Promotes Cancer Cell Survival and Mediates Immunosuppression in Clear Cell Renal Cell Carcinoma

Increased expression of tribbles homolog 3 predicts poor prognosis and correlates with tumor immunity in clear cell renal cell carcinoma: a bioinformatics study

Overexpression of the Transcription Factor ATF3 with a Regulatory Molecular Signature Associates with the Pathogenic Development of Colorectal Cancer

ATF3 Inhibits the Tumorigenesis and Progression of Hepatocellular Carcinoma Cells Via Upregulation of CYR61 Expression

Expression and Clinical Significance of Activating Transcription Factor 3 in Human Breast Cancer

Identification of C3 and FN1 as potential biomarkers associated with progression and prognosis for clear cell renal cell carcinoma

Activating transcription factor 3 is an antitumor gene synergizing with growth differentiation factor 15 to modulate cell growth in human bladder cancer

Systematic analyses of the role of prognostic and immunological EIF3A, a reader protein, in clear cell renal cell carcinoma

ITGB3 is a Novel Prognostic Biomarker and Correlates with Aberrant Methylation and Tumor Immunity in Clear Cell Renal Cell Carcinoma

Association Between the Atf3 Gene and Non-Small Cell Lung Cancer

ATXN3 promotes proliferation, stemness and motility of clear cell renal cell carcinoma cells by regulating S100A8 ubiquitination

STAC3 as a poor prognostic biomarker in renal clear cell carcinoma: relationship with immune infiltration

Prognostic biomarker CPEB3 and its associations with immune infiltration in clear cell renal cell carcinoma

TOX3 Inhibits Cancer Cell Migration and Invasion Via Transcriptional Regulation of SNAI1 and SNAI2 in Clear Cell Renal Cell Carcinoma.

High Expression of <i>TACC3</i> Is Associated with the Poor Prognosis and Immune Infiltration in Lung Adenocarcinoma Patients

TLR3 Serves as a Prognostic Biomarker and Associates with Immune Infiltration in the Renal Clear Cell Carcinoma Microenvironment

Decreased Expression of ATF3, Orchestrated by Β-Catenin/tcf3, Mir-17-5p and HOXA11-AS, Promoted Gastric Cancer Progression Via Increased Β-Catenin and CEMIP

Comprehensive Bioinformatics Analyses of APOBECs Family and Identification of APOBEC3D As the Unfavorable Prognostic Biomarker in Clear Cell Renal Cell Carcinoma.

Increased Expression of POLR3G Predicts Poor Prognosis in Transitional Cell Carcinoma.

A New CCCH-type Zinc Finger-Related Lncrna Signature Predicts the Prognosis of Clear Cell Renal Cell Carcinoma Patients